<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536131</url>
  </required_header>
  <id_info>
    <org_study_id>EK 1502/2014</org_study_id>
    <nct_id>NCT02536131</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease</brief_title>
  <official_title>Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal Investigation of intestinal microbiome, fecal inflammation markers, stress and&#xD;
      psychological variables in patients with irritable bowel syndrome and inflammatory bowel&#xD;
      disease undergoing gut-directed hypnotherapy (GHT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design is a within-subject design with assessment at 4 points in time. Data will be&#xD;
      collected 3-1 month before first GHT session (T1), immediately before first session (T2), at&#xD;
      the last session (T3), and 3-6 months after last session (T4).&#xD;
&#xD;
      Study patients will be recruited consecutively at the special outpatient-clinic for&#xD;
      psychosomatics at the division of Gastroenterology and Hepatology, department for Internal&#xD;
      Medicine III, University Hospital Vienna.&#xD;
&#xD;
      Patients undergo GHT in group setting, which has been shown to reduce irritable bowel&#xD;
      syndrome (IBS) symptoms and to increase psychological wellbeing. The GHT protocol used will&#xD;
      be the Manchester protocol of gut-directed hypnotherapy and consists of 10 weekly sessions&#xD;
      (45 minutes) with six up to eight patients per group over a treatment period of 12 weeks.&#xD;
&#xD;
      The following variables will be assessed using standardized questionnaires: anxiety and&#xD;
      depression (HADS-D), perceived stress (PSQ), resilience (CDRISC), and quality of life (visual&#xD;
      analogue scales). IBS symptoms will be captured by the IBS Severity Scoring System (IBS-SSS),&#xD;
      inflammatory bowel disease (IBD) disease activity via Harvey-Bradshaw-Index. Additionally,&#xD;
      medication intake and food supplements will be assessed.&#xD;
&#xD;
      Microbiome data will be gained by frozen stool samples, collected by patients at home.&#xD;
      Patients will be provided with a delivery kit to keep the samples frozen. Patients are asked&#xD;
      to collect the first stool of the day and not to change diet, medication and intake of&#xD;
      pre/probiotics during the hole study period, if possible (documented). At each time point&#xD;
      (T1-T4) patients are ask to bring two immediately frozen (stored in their home freezer)&#xD;
      double samples (2 stool samples within 1 week) to the hospital to be immediately stored at&#xD;
      minus 20 degree Celsius. If patients do not have a home freezer, stool will be collected and&#xD;
      frozen at the hospital.&#xD;
&#xD;
      Planned analyses comprise longitudinal and cross-sectional comparisons Intestinal&#xD;
      colonization will enter in the analyses according to an algorithm assigning values for an&#xD;
      increase or reduction of dysbiosis. Dysbiosis is hereby defined by the following markers:&#xD;
      reduction of fecal biodiversity, lowered occurrence of the species Bifidobacterium,&#xD;
      Lactobacillus and Faecalibacterium prausnitzi, increased occurrence of Enterobacteriaceae,&#xD;
      and a higher quotient Firmicutes:Bacteroidetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in gut microbiome as assessed through analyzing fecal samples</measure>
    <time_frame>7 days</time_frame>
    <description>Analysis of faeces by taxonomic and functional classification via 16s ribosomal ribonucleic acid (rRNA) sequencing with special regard to commensal microbiota and pathobionts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Stress Questionnaire</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>7 days</time_frame>
    <description>Total score as a measure of psychological distress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Scoring System for Irritable Bowel Syndrome</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal calprotectin</measure>
    <time_frame>1 day</time_frame>
    <description>Intestinal inflammation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harvey-Bradshaw-Index</measure>
    <time_frame>2 days</time_frame>
    <description>Disease activity index for IBD's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life visual analogue scales</measure>
    <time_frame>10 days</time_frame>
    <description>Visual analogue scales pertaining to physical, psychological and general wellbeing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI single symptom visual analogue scales</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>IBS</condition>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7-10 sessions gut-directed hypnotherapy within 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gut-directed hypnotherapy</intervention_name>
    <description>relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Gut-focused hypnotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IBS or IBD&#xD;
&#xD;
          -  Eligible for gut-directed hypnotherapy&#xD;
&#xD;
          -  Adult age (18-89)&#xD;
&#xD;
          -  Sufficient knowledge of german language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe somatic or psychiatric illness&#xD;
&#xD;
          -  Operations of the GI tract&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Moser, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gabriele Moser</investigator_full_name>
    <investigator_title>Prof. Dr. Gabriele Moser</investigator_title>
  </responsible_party>
  <keyword>Psychosomatics</keyword>
  <keyword>Gastroenterology</keyword>
  <keyword>Psychoneuroimmunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

